STK25 as a regulator of lipid accumulation by Chursa, Urszula
 STK25 as a regulator of lipid 
accumulation 
 
 
 
Urszula Chursa 
 
 
 
Lundberg Laboratory for Diabetes Research 
Department of Molecular and Clinical Medicine 
Institute of Medicine 
Sahlgrenska Academy, University of Gothenburg 
 
 
 
 
 
 
 
 
Gothenburg 2018 
  
 
Cover illustration: “A mysterious life of lipid droplets” by Urszula 
Chursa. Image of differentiated 3T3-L1 cells, generated with Deep 
Dream Generator.  
 
 
 
 
 
 
 
 
 
 
 
 
 
STK25 as a regulator of lipid accumulation 
© Urszula Chursa 2018 
urszula.chursa@gu.se 
 
ISBN 978-91-7833-101-7 (PRINT)  
ISBN 978-91-7833-102-4 (PDF) 
 
Printed in Gothenburg, Sweden 2018 
Printed by BrandFactory 
Nic dwa razy 
 
Nic dwa razy się nie zdarza 
i nie zdarzy. Z tej przyczyny 
zrodziliśmy się bez wprawy 
i pomrzemy bez rutyny. 
 
Choćbyśmy uczniami byli 
najtępszymi w szkole świata, 
nie będziemy repetować 
żadnej zimy ani lata. 
 
Żaden dzień się nie powtórzy, 
nie ma dwóch podobnych nocy, 
dwóch tych samych pocałunków, 
dwóch jednakich spojrzeń w oczy. 
 
Wczoraj, kiedy twoje imię 
ktoś wymówił przy mnie głośno, 
tak mi było, jakby róża 
przez otwarte wpadła okno. 
 
Dziś, kiedy jesteśmy razem, 
odwróciłam twarz ku ścianie. 
Róża? Jak wygląda róża? 
Czy to kwiat? A może kamień? 
 
Czemu ty się, zła godzino, 
z niepotrzebnym mieszasz lękiem? 
Jesteś - a więc musisz minąć. 
Miniesz - a więc to jest piękne. 
 
Uśmiechnięci, współobjęci 
spróbujemy szukać zgody, 
choć różnimy się od siebie 
jak dwie krople czystej wody. 
 
Wisława Szymborska 
 
 
 
 
 
Nothing twice 
 
Nothing can ever happen twice. 
In consequence, the sorry fact is 
that we arrive here improvised 
and leave without the chance to 
practice. 
 
Even if there is no one dumber, 
if you're the planet's biggest dunce, 
you can't repeat the class in summer: 
this course is only offered once. 
 
No day copies yesterday, 
no two nights will teach what bliss is 
in precisely the same way, 
with precisely the same kisses. 
 
One day, perhaps some idle tongue 
mentions your name by accident: 
I feel as if a rose were flung 
into the room, all hue and scent. 
 
The next day, though you're here with 
me, 
I can't help looking at the clock: 
A rose? A rose? What could that be? 
Is it a flower or a rock? 
 
Why do we treat the fleeting day 
with so much needless fear and 
sorrow? 
It's in its nature not to stay: 
Today is always gone tomorrow. 
 
With smiles and kisses, we prefer 
to seek accord beneath our star, 
although we're different (we concur) 
just as two drops of water are. 
 
Translated by Clare Cavanagh and 
Stanislaw Baranczak 
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ABSTRACT 
Type 2 diabetes mellitus (T2DM) and nonalcoholic steatohepatitis 
(NASH), a progressive form of nonalcoholic fatty liver disease 
(NAFLD), have become widespread metabolic disorders that have 
reached epidemic proportions. Obesity, with ectopic lipid 
accumulation, is the main factor for the development and subsequent 
progression of T2DM and NASH. To develop effective 
pharmacological treatment strategies against these metabolic 
diseases, it is important to understand molecular mechanisms that 
control ectopic lipid deposition and insulin resistance.  
Previous findings demonstrate that inhibition of serine/threonine 
protein kinase (STK25) leads to protection against HFD-induced liver 
steatosis and improved whole-body glucose tolerance and insulin 
sensitivity. In contrast, STK25 overexpression results in aggravated 
steatosis, promoting NAFLD and driving NASH development. Based 
on these studies, we investigated STK25 in the development of diet-
induced NASH, described in Paper I. In this project, we found that 
mice fed methionine-choline deficient (MCD) diet were protected 
against NASH development following depletion of STK25. However, 
STK25 overexpression led to development of a more severe NASH 
phenotype when mice were challenged with MCD diet.  
In Paper II, we found that overexpression of STK25 leads to increased 
ectopic lipid storage, fibrosis and inflammation in skeletal muscle of 
mice fed high-fat diet (HFD). Moreover, STK25-overexpressing mice 
had decreased in vivo insulin-stimulated glucose uptake, decreased 
endurance exercise performance and impairments in β-oxidation.  
We also explored the role of STK25 in adipocyte lipid accumulation 
and maturation in Paper III using 3T3-L1 preadipocyte cells. We found 
that 3T3-L1 cells accumulated less lipid droplets and had several 
markers of adipocyte maturation reduced when STK25 was silenced 
prior to differentiation. Furthermore, we show a significant positive 
correlation between adipogenesis markers and STK25 expression in 
human adipose tissue.  
Taken together, work in this thesis contributes to the concept that 
STK25 is a potential drug target for prevention and/or treatment of 
obesity-associated T2DM, NAFLD and NASH.  
Keywords: STK25, T2DM, NAFLD, NASH, ectopic lipid accumulation, 
metabolism.  
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 SAMMANFATTNING PÅ SVENSKA 
Typ 2 diabetes mellitus (T2DM) och non-alcoholic steatohepatitis 
(NASH), en progressiv form non-alcoholic fatty liver disease (NAFLD), 
har uppnått epidemiska proportioner och blivit ett globalt hot mot 
människors hälsa. Fetma, framförallt bukfetma, och leverförfettning är 
huvudfaktorerna i utvecklingen och progressionen av T2DM och 
NASH. För att utveckla effektiva farmakologiska behandlingsstrategier 
mot dessa metaboliska sjukdomar är det viktigt att förstå molekylära 
mekanismer som styr ektopisk lipidinlagring och insulinresistens. 
Tidigare fynd visar att hämmandet av serin/threonin proteinkinas 
(STK25) leder till skydd mot leverförfettning orsakad av högfettsdiet, 
samt förbättrad glukostolerans och insulinkänslighet i hela kroppen. 
Däremot leder överuttryck av STK25 till ökad lipidinlagring i levern, 
som främjar NAFLD-utveckling och driver utvecklingen av NASH.  
I denna avhandling fann vi att möss som saknar STK25 skyddades 
mot NASH-utveckling medan överuttryck av STK25 ledde till en 
snabbare utveckling av NASH. Vi har funnit att överuttryck av STK25 
leder till ökad ektopisk lipidansamling, fibros och inflammation i 
skelettmuskulaturen hos möss som matas med högfettsdiet. 
Dessutom hade STK25-överuttryckande möss minskat sin 
insulinkänslighet, hade försämrad muskeluthållighet och nedsatt 
fettmetabolism. Vi har dessutom undersökt STK25 roll vid fettcellernas 
lipidansamling och mognad med hjälp av 3T3-L1 celler. Vi fann att 
3T3-L1-celler utvecklade mindre lipiddroppar och hade reducerade 
markörer av fettcell-mognad när STK25 tystades före cell 
differentieringen. Vidare visar vi en signifikant positiv korrelation 
mellan fettcellernas differentieringsmarkörer och STK25 genuttryck i 
human fettvävnad. 
Sammanfattningsvis visar vi att STK25 är ett potentiellt intressant 
protein för förebyggande och/eller behandling av T2DM, NAFLD och 
NASH och relaterade metabola komplikationer.  
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ABBREVIATIONS 
ACC Acetyl-CoA carboxylase 
ALT Alanine aminotransferase 
AMPK AMP-activated kinase 
ATGL Adipose triacylglycerol lipase 
C/EBP CCAAT/enhancer-binding protein 
CAT Catalase 
CYPE21 Cytochrome P450 2E1 
DAG Diacylglycerol 
DNA Deoxyribonucleic acid 
DNL De novo lipogenesis 
EDL Extensor digitorum longus 
EHC Euglycemic-hyperinsulinemic clamp 
ER Endoplasmatic reticulum  
FFA Free fatty acid 
GM130 Golgi matrix protein 130 
GSH Glutathione 
HCC Hepatocellular carcinoma 
HFD High fat diet 
HSL Hormone sensitive lipase 
LCFA Long-chain fatty acid 
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LD Lipid droplet 
LPL Lipoprotein lipase 
MAG Monoacylglycerol 
MCD Methionine-choline deficient  
MSC Mesenchymal stem cells 
MST Mammalian Sterile20-like 
NAFLD Nonalcoholic fatty liver disease 
NASH Nonalcoholic steatohepatitis  
NEFA Non-esterified free fatty acid 
PPARγ Peroxisome proliferator-activated receptor gamma 
ROS Reactive oxygen species 
STK25 Serine/threonine protein kinase 25 
STRIPAK Striatin-interacting phosphatase and kinase 
T2DM Type 2 diabetes mellitus  
TAG Triacylglycerol 
TBARS Thiobarbituric acid-reactive substances 
TEM Transmission electron microscopy 
VLDL Very low-density lipoprotein 
WAT White adipose tissue 
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1 INTRODUCTION 
 
Metabolic diseases and disorders are major challenges in the world 
today and include T2DM and NASH, both of which are related to 
ectopic fat accumulation including NAFLD and insulin resistance. 
Prevalence of T2DM is continuously rising. More than 400 million 
people were diagnosed with T2DM in year 2014 (World Health 
Organization). T2DM is highly prevalent in NAFLD (1). The main 
feature of it is hepatic steatosis, i.e.; liver triglyceride (TAG) 
accumulation (1). NAFLD progression to a more aggressive liver 
disorder, NASH, is described as a multiple hit mechanism (2). The first 
hit is considered to be metabolic insulin resistance, which promotes 
hepatic steatosis. Subsequent dysregulation of mitochondrial functions 
including de novo lipogenesis (DNL) and reduced ability of the liver to 
export fatty acids (FAs) promotes the second hit - accumulation of 
reactive oxygen species (ROS) causing oxidative stress. However, in 
these early stages of NASH, when mitochondrial dysfunction is not 
pronounced, mitochondrial adaptation in the liver is possible and the 
disorder pattern can reverse. This ability is unfortunately lost during 
NASH progression (3). When ectopic lipid accumulation is a fact and 
mitochondrial function is impaired, chronic oxidative stress mediates 
recruitment of inflammatory infiltrates, endoplasmatic reticulum (ER) 
stress and hepatocellular damage (4-6). Fibrosis, which is a predictor 
of cirrhosis, is an optional feature of NASH and does not always 
develop. However, approximately one fifth of NASH patients develop 
fibrosis, which further progresses to cirrhosis, hepatocellular 
carcinoma (HCC) and liver failure. A majority of obese T2DM patients 
has NAFLD and many of these develop NASH. Also, diabetic patients 
are at higher risk of developing hepatic fibrosis, HCC and other 
hepatic complications (7-9). 
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1.1 WAT  
White adipose tissue (WAT) plays a fundamental role in energy 
homeostasis (10). Placed in various anatomical locations in the body, 
WAT functions as a lipid storage/release and endocrine organ that 
provides energy and insulation as well as mechanical protection. The 
subcutaneous depot is associated with protective metabolic effects 
and insulin sensitivity, whereas increased visceral adipose tissue is 
associated with metabolic disorders and insulin resistance (11; 12). 
WAT has remarkable expandability properties. By either increasing 
the pool of differentiating fat cells (hyperplasia) or by increasing the 
size of the fat cells (hypertrophy) it can meet increased demands for 
fat storage.  
ADIPOGENESIS 
Mesenchymal stem cells (MSC) are pluripotent cells present in adults 
and can differentiate to mature adipocytes as needed. Preadipocytes 
are committed to the lineage, proliferate and undergo growth arrest 
before mitotic expansion during the terminal differentiation event. All 
these phases are tightly regulated by a number of transcription 
factors. The commitment of MSC to preadipocytes involves 
dissociation of an inhibitory complex with zinc-finger protein 423 
(ZFP423) and its translocation to the nucleus to activate peroxisome 
proliferator-activated receptor gamma (PPARγ) (13). PPARγ is the 
master regulator of adipogenesis and survival of mature adipocytes 
(14) and, together with several CCAAT/enhancer-binding proteins 
(C/EBPs), drives terminal differentiation (10; 13). Hyperplasia 
(expansion in adipose cell number), rather than hypertrophy (increase 
in adipocyte cell size) is considered to be metabolically beneficial 
when the excess dietary lipids need to be stored in adipose tissue (13; 
15-17) and limited adipogenesis in the subcutaneous depot is 
associated with ectopic fat accumulation and insulin resistance (18; 
19). 
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LIPID TURNOVER IN WAT 
WAT stores fat as TAGs and during periods of energy needs, it makes 
the stored energy accessible through lipolysis, releasing free fatty 
acids (FFAs). In this process, TAGs are hydrolyzed to FFA and 
glycerol by lipases. There are three known lipases, acting in response 
to starvation or other signals, providing cells with energy from fat fuels 
(20). Monoacylglycerol lipase (MAL), hormone-sensitive lipase (HSL) 
and adipose-triglyceride lipase (ATGL), which hydrolyze 
monoacylglycerol (MAG), diacylglycerol (DAG) and triacylglycerol 
(TAG), respectively (21). Lipolysis stimulation through cyclic 
guanosine monophosphate (cGMP)- or cyclic adenosine 
monophosphate (cAMP) -dependent activation of protein kinase G 
(PKG) or protein kinase A (PKA), respectively, leads further to 
activation of ATGL and HSL (22). FFAs released through lipolysis are 
bound to albumin, oxidized by skeletal muscle and liver, and re-
esterified by adipocytes. TAGs transported from intestine as 
chylomicrons and from liver as very low density (VLDL) particles are 
delivered to adipocytes by lipoprotein lipase (LPL) for TAG synthesis. 
LPL breaks down these TAGs into FFAs, which are further esterified 
to a glyceride-glycerol backbone. FFAs can also be taken up by 
adipocytes and used for TAG synthesis (11).  
Postprandial inhibition of lipolysis is due to elevated insulin levels, 
where insulin mediates cAMP degradation and thereby inactivation of 
PKA and its downstream targets (23; 24). Lipid overload in 
hypertrophic adipocytes leads to local tissue inflammation that 
becomes chronic with time, leading to increased tumor necrosis-
factor-α (TNFα), and other cytokines, secretion (25). TNFα is known 
to induce lipolysis and decrease TAG synthesis in adipocytes, leading 
to increased levels of circulating non-esterified FFAs (NEFAs). 
Inability to store excess lipids in the adipose tissue leads their 
deposition in other metabolically active organs, such as liver and 
skeletal muscle (26; 27). This ectopic lipid deposition induces 
lipotoxicity and enhances insulin resistance in these tissues (28; 29). 
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Obese and insulin-resistant subjects also have increased rate of non-
stimulated lipolysis, which further promotes dyslipidaemia (30; 31).  
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1.2 HEPATIC GLUCOSE AND LIPID 
METABOLISM  
As a central organ in glucose and fat homeostasis, liver not only 
stores glucose and lipids, it also provides skeletal muscle, heart and 
adipocytes with FFAs via very low-density lipoprotein (VLDL) particles. 
Moreover, carbohydrates delivered from the diet can be converted into 
FFAs following hepatic DNL. These FFAs are oxidized in the 
mitochondria or peroxisomes, esterified to TAGs and stored in small 
lipid droplets (LDs) or added to lipoprotein to form VLDLs for 
secretion. When FFAs are in abundance, ω-oxidation occurs in the 
ER.  
Under control of insulin, glucose is stored in liver as glycogen. When 
blood glucose levels drop, pancreatic α-cells secrete glucagon 
signaling to the liver to enhance glycogenolysis and gluconeogenesis, 
in order to release glucose from glycogen or increase its synthesis 
from lactate and amino acids. This process keeps glucose levels 
stable, which is crucial for tissues with constant glucose demand, such 
as brain (5; 32-34). Excess glucose can also provide glycerol 
backbone, which can be coupled with esterified FFAs and stored as 
TAGs or secreted as VLDL.  
LIVER IN NAFLD/NASH 
The most prevalent cause of NAFLD is dysfunctional adipose tissue 
and obesity (35), where increased FFA secretion is caused by 
impairments in insulin-mediated suppression of lipolysis (36) and 
chronic adipose tissue inflammation. Skeletal muscle glucose uptake 
is reduced due to excessive lipid uptake and decreased insulin 
sensitivity leading to compensatory hyperinsulinemia. Liver 
dysfunction in NAFLD is characterized by liver steatosis, increased 
gluconeogenesis, decreased glycogen synthesis, and increased 
release of hepatokines (37-39). Progression to NASH is due to 
subsequent multiple hits, with oxidative stress and hepatocellular 
damage being persistent events. 
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OXIDATIVE STRESS IN NAFLD/NASH 
ROS and reactive nitrogen species (RNS) generated by oxidative 
stress disrupt cellular processes by reacting with intracellular 
macromolecules, causing protein inactivation and denaturation, 
thereby changing signal transduction, causing DNA damage and lipid 
peroxidation (40; 41). Oxidative stress triggers inflammation, ER 
stress and reduced synthesis of endogenous antioxidants (42). 
Mitochondrial electron transport chain and DNA are especially 
sensitive to reactive oxidative stress. Mitochondrial β-oxidation in 
NAFLD is affected due to progressive FFAs overflow, resulting in 
electron leakage and leading to a vicious cycle of mitochondrial ROS 
generation in hepatocytes and mitochondrial dysfunction during 
progression to NASH (3; 43).  
LIVER INFLAMMATION AND HEPATOCELLULAR DAMAGE  
It is not a single feature, but hepatic steatosis, inflammation, fibrosis 
and ballooning give a collective score to rate activity of NAFLD and its 
progression to NASH (44; 45). Oxidative stress, which becomes 
chronic with time, leads to hepatocellular damage and recruitment of 
inflammatory infiltrates in the pathogenesis of NAFLD/NASH (4-6).  
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1.3 SKELETAL MUSCLE 
Skeletal muscles, with their high impact on systemic energy 
consumption, are responsible for the majority of the glucose disposal 
after a meal and, thus, play a key role in whole-body glucose 
homeostasis (46; 47). Glucose is taken up by skeletal muscle through 
insulin signaling pathways or contraction, both of which stimulate 
GLUT4 translocation to cell surface to take up glucose from the 
circulation (48). 
Skeletal muscle is heterogeneous both in its function and structure. 
Composed of myofibrils gathered together into fibers, which in turn are 
enclosed in fasciculi, skeletal muscle is a powerful machinery to 
generate force and movement. Skeletal muscle also plays a major role 
as a metabolically active tissue. It is appreciated that there are four 
types of fibers with different contractile and metabolic properties. 
However, two main categories are recognized. Fibers with slow 
contractile properties, low fatigue, high oxidative capacity, use FFAs 
as the preferable substrate in order to generate the energy. Second 
main category is the extreme opposite, containing fibers that contract 
fast and have high level of fatigue, with glycolytic properties and 
glucose as a preferable substrate. The four types of fibers that fall into 
these two categories belong either to one of them, or have the mixed 
properties of both. Skeletal muscle fibers have a remarkable property 
to switch their metabolic abilities depending on systemic energy 
demand. For example a fast-to-slow fiber type switch increases 
oxidative capacity of the muscle (49-51).  
ECTOPIC LIPID ACCUMULATION AND INSULIN RESISTANCE IN 
SKELETAL MUSCLE 
Obesity-induced WAT spillover, as FFAs, is delivered to other 
metabolic tissues, such as skeletal muscle and liver for storage (52). 
This ectopic storage of fat, especially in skeletal muscle and liver, is 
strongly associated with insulin resistance (28; 53). In fact, agents that 
reduce the ectopic lipid content in skeletal muscle and liver, redirecting 
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it to subcutaneous adipose tissue, have shown improvement in insulin 
sensitivity (17; 54). 
FFAs delivered to myocytes from circulation are stored as TAGs in 
LDs or directed to mitochondria for oxidation (55). FFAs were shown 
to play an important role in induction of insulin resistance and 
mitochondrial dysfunction in muscle cell culture (56; 57) and in human 
skeletal muscle (58; 59). 
Increased number of LDs in the skeletal muscle is not always 
connected to a pathological situation. Oxidative fibers in skeletal 
muscles of marathon runners store more LDs than muscles from less 
active individuals. This phenomenon, called athlete’s paradox, is 
positively correlated with insulin sensitivity (55; 60). However, 
excessive lipid storage in the glycolytic muscle fibers, at least in mice, 
has been shown to promote insulin resistance (61). In man, insulin 
resistance has been linked to increased intra-myocellular lipid content 
in a number of studies in past years (62-64). In obesity-associated 
insulin resistance, increase in intra-myocellular metabolites leads to 
quenched insulin action, mitochondrial dysfunction and oxidative 
stress, further worsening lipid accumulation and insulin resistance (55; 
65; 66). Impairment in skeletal muscle mitochondrial function has 
been observed in obese and T2DM subjects (67). 
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1.4 SERINE/THREONINE KINASE 25 (STK25) 
STK25 belongs to Sterile20 family of kinases, in the group of germinal 
center kinases (GCK). Sterile20 family of kinases contains a subfamily 
named Mammalian Sterile20-like (MST) family, which is further divided 
into subgroups: MST1, -2 and MST3/4/STK25. The second subgroup 
is a part of the striatin-interacting phosphatase and kinase (STRIPAK) 
complex; it has been shown to have a high impact on the regulation of 
the cytoskeleton and Golgi apparatus (68). Previous studies have 
demonstrated STK25 localization to the Golgi apparatus where it 
regulates cell migration and polarization. Moreover, interaction of 
STK25 and Golgi matrix protein 130 (GM130) promotes Golgi 
assembly (69). STK25 has a high expression in the brain (70) and has 
been widely described in neurodegenerative disorders (71-73), 
having, for example, a negative impact on neuronal cell migration (74). 
Several studies have shown oxidative stress influence on STK25 
function, where STK25 translocates to the nucleus and induces 
apoptosis (70; 75; 76). Notably, a study by one of these groups has 
recently shown that hepatic STK25 is significantly activated in mice 
after HFD, compared to mice fed a normal chow diet (77). 
It has been suggested that a central regulator of metabolism, AMP-
activated kinase (AMPK), regulates expression of STK25 (78). This 
study has created a wave of extensive research on STK25 
involvement in metabolic homeostasis, performed in our laboratory, 
exposing the STK25 impact on progress of diseases such as T2DM, 
NAFLD and NASH. Both in vivo and in vitro studies in various tissues 
and cell lines provided evidence that STK25 regulates metabolic 
balance between storing and oxidizing lipids, regulating whole body 
insulin and glucose homeostasis (79-85). Overexpression of STK25 in 
mice on high-fat diet has been shown to increase fasting plasma 
insulin and spontaneous activity, to reduce systemic glucose 
tolerance, insulin sensitivity and energy expenditure. Apart from 
adipocyte hypertrophy, overexpression of STK25 in mice leads to 
excessive accumulation of TAGs and increased expression of genes 
regulating lipid synthesis and repression of β-oxidation in liver and 
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muscle. In addition, liver glycogen levels were elevated in these mice, 
together with expression of genes regulating gluconeogenesis, 
glucose synthesis and FA synthesis (80; 82). Furthermore, there was 
a significant increase of STK25 mRNA expression in skeletal muscle 
of T2DM patients (86). On the other hand, mice lacking STK25 have 
opposite effects on almost all mentioned parameters, indicating 
beneficial aspects of low STK25 in challenged conditions (79; 85). 
Importantly, obese mice treated with Stk25 anti-sense 
oligonucleotides have shown a beneficial effect on the phenotype 
associated with obesity and insulin resistance in wild-type mice fed a 
high-fat diet (87). A recent study also shows an effect of STK25 in the 
regulation of progression of cardiovascular disease (88).  
A study in human hepatic cells has provided a suggested mechanism 
of STK25 function in lipid metabolism (Fig. 1). STK25 overexpression 
led to decreased β-oxidation and VLDL secretion in these cells and 
enhanced TAG synthesis. An inverse correlation was observed in 
human hepatic cells lacking STK25 expression. Moreover, there is a 
positive and significant correlation between STK25 mRNA expression 
and hepatic fat (81).  
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Figure 1. Schematic illustration of proposed model of 
STK25 action in regulation of lipid accumulation in human 
hepatocytes. Overexpression of STK25 suppresses LD 
catabolism through repressed -oxidation and VLDL-
secretion, and increases TAG synthesis and thereby LD 
accumulation. On the other hand, STK25 knockdown leads 
to reciprocal effects with increased -oxidation and VLDL-
TAG secretion, and reduced TAG synthesis in the liver 
cells. Figure acquired from (81). 
STK25 knockdown STK25 overexpression 
STK25 Lipid droplet 
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2 AIM 
 
The general aim of this thesis was to elucidate the metabolic impact of 
the kinase STK25 in the regulation of lipid metabolism, IR, T2DM and 
NAFLD/NASH progression.  
The specific aims of the three papers included in thesis were: 
Paper I. To investigate STK25 impact on NASH progression in 
short- term methionine and choline-deficient diet in 
Stk25 transgenic and Stk25 knockout mice.  
Paper II. To understand the role of STK25 in ectopic fat 
accumulation and insulin resistance in skeletal muscle 
of high-fat-fed mice. 
Paper III. To investigate the effect of STK25 on adipose cell 
maturation and lipid accumulation in 3T3-L1 cells. 
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3 EXPERIMENTAL PROCEDURES 
 
For detailed information about the experimental procedures, please 
see corresponding Material and Methods sections for Papers I, II and 
III. 
ETHICAL STATEMENT  
The Ethical Committee of the University of Gothenburg approved the 
study design and written informed consent was received from study 
participants after the purpose and the potential risks of the study were 
explained. Approval from Local Ethics Committee for Animal Studies 
at the Administrative Court of Appeals in Gothenburg was received 
prior to performing any experiments in mice.  
ANIMAL MODELS  
The transgenic mouse model overexpressing STK25 on the whole-
body level was generated, using C57BL/6N strain, by the Norwegian 
Transgenic Center in Oslo. For detailed information, see (82). One of 
the significant limitations of the animal model used in this study is the 
high expression of STK25 in transgenic animals. There are no 
reported cases in animals or humans with levels of STK25 expression 
being as high as in Stk25 transgenic animals. This limits the 
translation of the current results to normal human pathophysiology 
and needs to be further examined and related to expression levels. 
The whole-body Stk25 knockout mice were a gift from Prof. B. Howell 
(Department of Neuroscience and Physiology, State University of New 
York Upstate Medical University, Syracruse, New York, USA), and 
were previously described in (74). Heterozygous Stk25 knockout mice 
were backcrossed to a C57BL6/J genetic background as described in 
(79). 
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Since Stk25 transgenic and Stk25 knockout mice have different 
genetic backgrounds, C57BL6/N and C57BL6/J, respectively; it is 
problematic to directly compare these groups. Thus, both need to be 
compared to their respective wild-type littermates. This results in the 
need of excessive breeding of additional animals to have a direct 
comparison between Stk25 transgenic, Stk25 knockout and one wild-
type group, but would have been beneficial in the interpretation of the 
results generated. 
Mice were housed in temperature-controlled (21 °C) facility with 12-
hour light-dark cycle, with free access to water and chow food. Mice 
were weaned at 3-5 weeks of age. Age-matched, male mice were 
used in the experiments and knockout and/or transgenic mice were 
compared to their corresponding wild-type littermates throughout this 
thesis. Mice were fed corresponding diets with start at 6 weeks of age 
with free access to food and water.  
In Paper I, Stk25 knockout and transgenic mice, and their respective 
wild-type littermates were fed pelleted methionine/choline-deficient 
(MCD) diet or pelleted control chow diet for 4 weeks. There are 
various animal models for induction of NAFLD, from genetic to dietary 
as well as a combination of both (5). We have chosen a diet-induced 
animal model, where mice received MCD diet during 4 weeks. 
Characteristic consequences of this diet include impairment in 
mitochondrial function, hepatic TAG accumulation, development of 
fibrosis, and NASH morphology. It is an effective and time-saving 
treatment. However, MCD diet is challenging for animals, making 
them cachectic. Animals have low levels of plasma TAG and no 
insulin resistance. These characteristics do not correspond to the 
typical NASH in humans (5).  
In the experimental setup in Paper II, Stk25 transgenic mice and their 
respective wild-type littermates were fed either pelleted HFD (45 kcal 
% fat) or pelleted control chow diet for 18 weeks. 
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EUGLYCEMIC-HYPERINSULINEMIC CLAMP  
In order to evaluate degree of insulin sensitivity in metabolic tissues in 
vivo, a euglycemic-hyperinsulinemic clamp study was performed in 
conscious mice. Post high-fat diet Stk25 transgenic mice were 
anesthetized. A catheter was inserted intravenously into the jugular 
vein and steadily connected to Vascular Access Button anchored to 
the neck area. Mice were given 3-4 days to recover from the surgery 
in a single-cage manner.  
A catheter coupled directly to the circulatory system enabled constant 
and controlled administration of insulin and glucose intravenously. In 
the beginning of the experiment, a bolus of insulin was injected to 
suppress hepatic glucose production. Thereafter, insulin was 
administrated at a stable rate to maintain systemic insulin levels. As 
the hyperinsulinemic state was reached, glucose was infused to reach 
a steady-state rate at euglycemia. The infusion rate of the glucose has 
a direct correlation to how insulin sensitive the body is. However the 
systemic insulin sensitivity can give false information about organ-
specific insulin sensitivity if the individual organs have differential 
insulin sensitivity. For that reason a bolus of radioactive-labeled 
glucose was given to measure tissue-specific glucose metabolism.  
ENDURANCE EXERCISE  
Aerobic exercise capacity was examined using treadmill-running test, 
where distance and total time were quantified. Thorough conducted 
acclimatization prior to the exercise test was performed to familiarize 
mice with the treadmill and reduce the stress of being handled. In the 
beginning of the test, mice started to run at established speed, which 
was increased continuously until the maximum speed adjusted for 
mice was reached. The test was terminated when the mice reached 
fatigue by spending 20 seconds or more at the base of the treadmill 
despite physical encouragement in form of mild poking. The test was 
performed at week 17 of the high-fat diet. Mice were allowed to 
recover 1 week prior to the termination. 
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TISSUE COLLECTION  
Mice were terminated after 4 hours of food withdrawal, by overdose of 
anesthetics. Subsequently, blood was collected through heart 
puncture and stored frozen for analysis of plasma metabolites. 
Tissues were dissected and stored in liquid nitrogen for further 
analysis. Tissues for histological analysis were fixed in 
paraformaldehyde for 24 h and, thereafter, stored in ethanol until 
embedded in paraffin block, or embedded in optimal cutting 
temperature compound directly after dissection, slowly immersed in 
liquid nitrogen and stored at -80 °C.  
Whole-body perfusion with glutaraldehyde, sodium cacodylate and 
sodium azide was performed in order to fixate gastrocnemius muscle 
and liver. Thereafter, the tissues were collected for transmission 
electron microscopy, and stored in fixatives.  
Gastrocnemius muscles determined for proteomic and 
phosphoproteomic analysis were heat-stabilized immediately after 
dissection. Tissues naturally contain enzymes such as proteases, 
phosphatases and peptidases that induce biological changes to 
proteins post-dissection. Through rapid heat inactivation of the 
muscles, these enzymes are permanently inactivated and the proteins 
are preserved in their natal state, making proteome analysis more 
accurate.  
CELL CULTURE  
Following adherent cell lines have been used in this thesis – L6 
myoblasts, HepG2 cells, immortalized human hepatocytes and 3T3-L1 
cells.  
HepG2 cells were originally isolated from liver biopsy of hepatocellular 
carcinoma cells found in a 15-year old male. IHH cells, on the other 
hand, are derived from a 59-year old male donor, suffering from colon 
cancer metastasis. Although both cell lines have similar lipoprotein 
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metabolism, HepG2 cells secrete LDL-like particles similar in size to 
plasma LDL, but different in their composition when compared to 
either LDL or VLDL particles found in plasma (89). 
L6 cells are mononuclear myoblasts isolated from rat skeletal muscle. 
When differentiated, L6 cells fuse into multinuclear myotubes.  
Mouse fibroblast cell line, 3T3-L1, effectively undergoes a pre-adipose 
to adipose-like conversion when stimulated with differentiation 
cocktail. Cells were grown to confluence and left intact for some days, 
in order to enter a resting state that is necessary for the differentiation 
process. Thereafter, differentiation medium was added, including pro-
differentiator agents - insulin, dexamethasone and 3-isobutyl-1-
methylxanthine. After few days of the differentiation, lipid accumulation 
was apparent. Differentiated cells are considered to be mature at day 
9-12. Due to transient transfections, which were performed prior to cell 
cycle arrest, cells were used at days 4-6 after the differentiation.  
Transient overexpression of myoblast- and hepatic cell lines was 
performed with pFLAG-STK25 or an empty control plasmid. Small 
interfering RNA was used for transient Stk25 knockdown in hepatic 
cell lines and the undifferentiated pre-adipocyte cell line. Efficiency of 
all transfections was facilitated using Lipofectamine reagents, 
consisting of specially designed cationic lipids. These liposomes and 
nucleic acid form a positively charged complex, mediating a fusion 
with negatively charged cell membrane possibly through endocytosis.  
PROTEOMICS  
Proteomics and phosphoproteomics have been applied in order to 
expose global changes in gastrocnemius muscle proteome between 
the genotypes. After purification, proteins were digested to peptides, 
eliminating the physico-chemical properties of the proteins and making 
the analysis more sensitive. Such peptides are rich in information and 
easier to interpret than full-length proteins, which might be processed 
and modified. Phosphorylation is an essential post-translational 
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protein modification, changing state of the protein activity. It is 
involved in all physiological and pathological processes. However, it is 
a rare modification making it difficult to detect in a total peptide 
sample. For that reason, samples determined for phosphoproteomic 
analysis were enriched in phosphopeptides using titanium dioxide that 
have a high affinity for phosphopeptides. Samples were marked with 
isobaric mass tagging reagents making it possible to directly compare 
between protein expression profiles in all the samples. Abundance of 
the total proteins and activity of the proteins through phosphorylation 
was analyzed with liquid chromatography mass spectrometry (LC-
MS). Sample processing and analysis have been performed in 
collaboration with the Proteomics Core Facility at University of 
Gothenburg. 
CARNITINES/ACYLCARNITINES MEASUREMENT  
Carnitine can be either taken up from the diet, or synthesized from 
amino acids, mainly in the liver. Fatty acids are transported into 
mitochondria by carnitines, in order to generate energy in the process 
of β-oxidation. Mitochondria-rich tissues, such as skeletal muscle and 
heart, contain highest levels of carnitines and acylcarnitine. 
Acylcarnitine extraction and analysis was performed using hydrophilic 
interaction liquid chromatography tandem mass spectrometry (HILIC-
MS/MS) (90) to detect impairments in FA β-oxidation . This method is 
simpler and more accurate than the conventional methods described 
previously in the literature, including more simple sample preparation 
that includes organic solvent for protein precipitation and labeled 
internal standards. Briefly, gastrocnemius muscles were homogenized 
in methanol. The samples were centrifuged and acetonitrile-methanol 
solution containing the deuterated reference standards was added to 
the sample supernatants. The analysis was made using multiple 
reaction monitoring and quantification was made against the internal 
standards. Sample processing and analysis have been performed in 
collaboration with Wallenberg Laboratory at the University of 
Gothenburg, Sahlgrenska University Hospital.  
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PROTEIN EXTRACTION AND WESTERN BLOT 
Cells and tissues were mechanically homogenized in the presence of 
lysis buffer containing protease inhibitor cocktail, to prevent 
degradation of proteins. Proteins were purified through a series of 
centrifugation steps. Protein concentration was determined using 
colorimetric BCA assay, where a mixture of alkaline medium and 
cupric sulfate was added to the extracted protein sample. This caused 
reduction of the Cu+2 to Cu+1, which bound to BCA creating a colored 
product that was quantified using spectrophotometer and compared to 
known protein standards.  
Western blot is a widely used antibody-based technique for detection 
and analysis of proteins. Prior to electrophoresis, proteins tertiary and 
quarternary structures were disrupted with heat and β-
mercaptoethanol; a reducing agent that breaks the disulfide bonds 
holding the structures. This makes the epitope more accessible for the 
primary antibody later in the detection process. Denatured proteins 
were thereafter loaded onto porous polyacrylamide gel to which 
voltage was applied. This enables proteins to separate through the gel 
and, depending on size, the proteins will migrate with different 
velocities. Proteins immobilized on the gel were relocated onto 
nitrocellulose membrane using semidry transfer, based on the same 
electro-mobility principle. To ensure that the proteins were transferred, 
membrane was stained with Ponceau S to visualize proteins. 
Membrane was incubated with non-fat milk solution to permanently 
cover the parts of the membrane not occupied by proteins, to reduce 
unspecific binding of the antibodies. Horseradish peroxidase (HRP)-
conjugated secondary antibody was bound to a primary antibody, 
which was specifically bound to the epitope on the protein of interest. 
Chemiluminescence detection system was used to expose marked 
proteins. Briefly, HRP is an enzyme that catalyzes the oxidation of a 
luminol peroxide detection agent. This results in emission of light, 
which is further increased with chemicals in reaction known as 
enhanced chemiluminescence (ECL). Intensity of the signal is 
proportional to amount of the protein on the blot.  
STK25 AS A REGULATOR OF LIPID ACCUMULATION  
24 
TRANSMISSION ELECTRON MICROSCOPY  
Transmission electron microscopy exposes details and complexity of 
cellular components, which cannot be assessed through light 
microscopy. For ultra-structural preservation, tissue was fixated in 
glutaraldehyde and postfixated in osmium tetroxide. While 
glutaraldehyde rapidly preserves structure of proteins and other 
macromolecules bound to them, osmium tetroxide reacts slowly with 
proteins and additionally fixates double bonds of unsaturated lipids. 
Imagining of organic molecules in transmission electron microscopy 
depends in large scale on the differences in their electron density. 
Additionally to its fixative properties, osmium tetroxide reduces onto 
certain macromolecules enhancing contrast of electron-dense areas. 
After fixation, samples were dehydrated in ethanol to enable efficient 
embedding in plastic for ultrathin sectioning with a diamond knife in a 
microtome. Sections were lastly stained with other heavy metals – 
uranyl acetate and lead citrate, to further increase contrast of electron 
dense areas. Sample processing and analysis have been performed 
in collaboration with the Centre for Cellular Imaging Core Facility at 
the University of Gothenburg. 
HISTOLOGY 
One of the most traditional methods for histological evaluation is 
staining with hematoxylin and eosin. Hematoxylin stains acidic 
structures in the cell, such as nucleic acids, giving a blue-purple color. 
Eosin, on the other hand, is an acidic, negatively charged dye. Eosin 
reacts with basic structures, such as proteins, staining the cytoplasm 
pink.  
Picrosirius red was used to stain collagen types I, II and III. However, 
it stains also other, non-collagen molecules. Picrosirius red is an 
elongated birefringent molecule and when bound to collagen it orients 
parallel to collagen fibrils enhancing their natural birefringence, and 
resulting in a bright red staining of collagen fibers when examined in a 
bright field microscope with polarized light.  
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Periodic acid-Schiff staining was used to identify glycogen deposition 
in the sections. Primarily periodic acid was added to a tissue section, 
oxidizing hydroxyl groups of carbohydrates, such as glycogen, to form 
aldehydes in the oxidation process. When Schiff reagent was added, it 
reacted with the aldehydes producing bright magenta color.  
Lipids were visualized using Nile Red and Oil red O stainings. As the 
lipids are extinguished in the process of de-paraffinization of paraffin 
sections, frozen sections or formalin-fixated cells were used. Nile Red 
is a lipophilic dye. Being strongly fluorescent in hydrophobic 
environment, Nile Red detects membranes and lipid droplets, without 
disrupting them. Oil red O, on the other hand, is a fat-soluble diazole 
dye. It stains most hydrophobic and neutral lipids, such as DAGs, 
TAGs and cholesterol esters, leaving unstained polar lipids, such as 
ceramides, phospholipids and sphingolipids.  
Mitochondria retain their enzymatic activity of the electron transport 
chain after dissecting the tissue. To access mitochondrial respiratory 
capacity in histological manners, we have stained mitochondria in 
frozen sections and live cells with MitoTracker Red stain and standard 
enzymatic stainings. MitoTracker Red staining contains thiol-reactive 
chloromethyl moiety, which accumulate in active mitochondria where it 
is oxidized leading to emission of fluorescent light.  
Enzymatic activity staining was done for NADH:ubiquinone 
oxidoreductase (complex I), succinate:ubiquinone oxidoreductase 
(complex II) and Cytochrome c oxidase (complex IV). The principle of 
these stainings is to add an electron donor specific for respective 
complex in order to obtain a colored product. In the complex I staining, 
NADH serves as an electron donor. Nitro blue tetrazolium will catch 
the electron, causing its reduction to a blue-colored formazan product. 
As many other compartments of the muscle cell contain NADH-
oxidizing enzymes, this stain is not exclusive for complex I. 
Conversely; complex II and IV stainings show high specificity for 
mitochondria. In the complex II staining, succinate is the electron 
donor. When added, succinate is oxidized to fumarate and releases 
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hydrogen. The hydrogen will reduce the nitro blue tetrazolium to form 
formazan, as in complex I stain. Brown color is produced when 3,3´-
diaminobenzidine (DAB) donates electrons for cytochrome c. Reduced 
cytochrome c further transfers electrons to oxygen, a reaction that is 
coupled by complex IV of the electron transport chain.  
Antibody based stainings were done to analyze proteins of interest 
using specific epitopes of these proteins. Either monoclonal or 
polyclonal unconjugated antibodies were used. Secondary antibody 
was always species-matched to the primary. Secondary antibody was 
conjugated either to a fluorochrome or to biotin. In the second case, 
an additional step was applied for the protein detection. Streptavidin 
conjugated DAB was added after incubation with the secondary 
antibody. DAB was oxidized when hydrogen peroxide was added, 
creating a brown color. Fluorochromes are small organic molecules 
holding one or more aromatic rings. Fluorochromes do not need any 
chemical activation as such; instead they absorb light energy and 
instantly emit light energy at a higher wavelength. A great advantage 
of the immunofluorescence is the possibility of detecting up to 5 
fluorochromes, i.e. 5 different proteins, in the same staining. 4’,6-
diamidino-2-phenylindole dye was used as a nuclear stain. Its blue-
fluorescence is enhanced greatly upon binding to AT-rich regions of 
double stranded DNA.  
OXIDATIVE STRESS MEASUREMENT  
Intracellular ROS functions contribute to physiological conditions but 
increased levels, known as oxidative stress, cause damage to the cell. 
In order to evaluate oxidative stress levels in Paper II, we have used a 
number of assays. Thiobarbituric acid-reactive substances (TBARS) 
display lipid peroxidation, indicating cellular injury through lipid 
peroxidation – an indicator of oxidative stress. Catalase (CAT) and 
glutathione (GSH) are responsible for H2O2 decomposition, thus low 
levels of these antioxidant enzymes indicate high oxidative stress, due 
to high amounts of ROS. 
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mRNA AND qRT-PCR 
For gene expression analysis, total RNA extracted from tissue- or cell 
samples was transcribed into complementary DNA (cDNA) by a 
reverse transcription PCR (RT-PCR) reaction, as it is more stable than 
RNA. Thereafter, cDNA was used as a template for the quantitative 
real-time PCR reaction (qPCR). Ribosomal housekeeping gene, 18S, 
was used to normalize the gene expression data. TaqMan probes and 
assays for qPCR have been used and analyzed according to the 
Minimum Information for Publication of Quantitative Real-Time PCR 
Experiments (MIQE) guidelines (91).  
STATISTICAL ANALYSES 
The experimental results are presented as means ± the standard error 
of the mean in all Papers. Statistical significance between the groups 
was evaluated using unpaired two-tailed Student’s t test and, between 
more than 2 groups, by analysis of two-way ANOVA followed by 
Turkey’s (Paper I, II, III) or Games-Howell (Paper III) post hoc test. 
Correlation data in human studies was assessed by Spearman’s rank 
correlation (Paper I and III) analysis after Kolmogorov-Smirnov test 
(Paper I) was performed to assess normality of the data. Statistics 
were calculated using IBM SPSS Statistics version 22 or Microsoft 
Excel. P<0.05 was considered statistically significant.  
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4 RESULTS AND DISCUSSION 
 
In this section, the main results from Paper I, II and III are 
summarized. Details of the results can be found in the separate 
Papers.  
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4.1 PAPER I: STK25 IS A CRITICAL 
DETERMINANT IN NONALCOHOLIC 
STEATOHEPATITIS 
 
The impact of STK25 on NASH progression was studied in short-term 
MCD diet-fed Stk25 transgenic and Stk25 knockout mice and also 
characterized in human liver biopsies.  
We have previously seen increased hepatic steatosis in Stk25 
transgenic mice, and the opposite in Stk25 knockout mice, on high-fat 
diet (79-82). Results from these studies indicate a negative impact on 
hepatic physiology caused by whole-body overexpression of STK25, 
and reciprocal benefits of the absence of STK25, supporting an 
important role of STK25 on hepatic lipid metabolism. 
First hit in NASH includes hepatic steatosis together with 
mitochondrial dysregulation. Consistent with previous observations in 
high-fat-fed mice, we found that after challenge with a MCD diet, 
Stk25 transgenic mice developed marked macro- and micro-vesicular 
hepatic steatosis with large lipid droplets, while hepatic lipid deposition 
in Stk25 knockout mice resembled healthy liver of chow-fed wild-type 
mice, without steatosis. TEM analysis revealed abnormal mitochondria 
in Stk25 transgenic mice, possibly indicating dysfunctional 
mitochondria in the livers of these animals, which was also supported 
by MitotrackerRed analysis of active mitochondria. 
Second hit involves increased hepatic oxidative stress (3). We 
measured several markers of hepatic oxidative stress and antioxidant 
defense. Hepatic TBARS levels and CAT activity in Stk25 knockout 
mice were equal to the respective wild-type mice on chow diet, 
indicating lack of oxidative stress and a proper antioxidant protection, 
respectively. Interestingly, a level of hepatic antioxidant enzyme, GSH, 
in Stk25 knockout livers was the highest among all the groups, 
including chow-diet mice. On the other hand, livers of Stk25 
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transgenic mice had elevated levels of 4-HNE, DHE and TBARS, 
indicating high lipid peroxidation and oxidative stress.  
Furthermore, we measured hepatic protein expression of the fatty acid 
oxidation proteins acetyl-CoA carboxylase 1 (ACOX1) and cytochrome 
P450 2E1 (CYP2E1). Alterations in CYP2E1 levels are associated 
with microsomal lipid peroxidation in NASH (42; 92; 93). In contrast to 
CYP2E1, which is involved in microsomal ω-oxidation, ACOX1 
functions in peroxisomal fatty acid β-oxidation pathway. No 
differences in CYP2E1 were observed between the groups. However, 
hepatic expression of ACOX1 in Stk25 transgenic mice was 
significantly elevated.  
Oxidative stress, which becomes chronic with time, leads to 
hepatocellular damage and recruitment of inflammatory infiltrates in 
the pathogenesis of NASH (4-6). The excessive liver cell apoptosis 
and severely damaged hepatocytes found in Stk25 transgenic mice, 
and the absence of these features in the livers of Stk25 knockout 
mice, have further confirmed the likely STK25 involvement in 
progression to NASH. Stk25 transgenic mice also had increased 
alanine aminotransferase (ALT) levels in serum, further supporting 
hepatocellular injury. In contrast, serum levels of ALT in Stk25 
knockout mice were significantly lower compared to the respective 
controls fed MCD diet.  
Excessive steatosis and oxidative damage increase risk of NASH. 
T2DM patients are at higher risk of developing advanced hepatic 
fibrosis, causing progression to cirrhosis and eventually hepatocellular 
carcinoma (7-9). Measurements of fibrosis by histological evaluation 
and biochemical assays revealed prominent hepatic fibrosis in Stk25 
transgenic mice while it was very restricted in livers of Stk25 knockout 
mice.  
In view of increased hepatocellular damage and fibrosis in Stk25 
transgenic mice, inflammatory cell infiltration was clearly expected. 
Immunostaining also revealed a markedly increased infiltration of 
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inflammatory cells in livers of Stk25 transgenic mice. Particularly, the 
presence of Ly6C positive cells, known to be associated with chronic 
inflammation and fibrogenesis (94), indicated that Stk25 transgenic 
mice have developed progression to NASH. As expected, levels of 
inflammatory infiltrates were minor in Stk25 knockout livers. Also, 
characteristic aggregations of inflammatory cells were observed 
mainly in livers of Stk25 transgenic mice. These characteristics of 
progressive inflammation were absent in Stk25 knockout livers.  
Previously, we have reported that STK25 mRNA expression also 
correlates positively with human liver steatosis (81). In the present 
study, we found a significant positive correlation between STK25 
mRNA expression and markers of NASH in human liver biopsies 
supporting a role of STK25 in the progression of this disease in man.  
Taken together, this extensive work in mouse models and human liver 
biopsies support an important role of STK25 in the progression of 
NAFLD to severe NASH (Fig. 2) 
 
Figure 2. Reciprocal responses to the MCD-diet-induced 
development of NASH in Stk25 knockout and Stk25 
transgenic mice. Figure acquired from Paper I. 
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4.2 PAPER II: OVEREXPRESSION OF PROTEIN 
KINASE STK25 IN MICE EXCARBATES 
ECTOPIC LIPID ACCUMULATION, 
MITOCHONDRIAL DYSFUNCTION, AND 
INSULIN RESISTANCE IN SKELETAL 
MUSCLE 
 
In this study we aimed to evaluate involvement of STK25 in ectopic 
lipid deposition, insulin sensitivity and mitochondrial dysfunction in 
skeletal muscle.  
In order to investigate the expression of STK25 in skeletal muscle, we 
performed protein analysis by western blot on white (glycolytic) and 
red (oxidative) muscle. Quantification of protein expression showed 
significantly higher STK25 in the white portion of the gastrocnemius 
muscle in wild-type mice fed HFD, compared to the red portion of the 
same muscle. Interestingly, there was a significant alteration in fiber 
diameter in the MHC2b fibers in the Stk25 transgenic gastrocnemius, 
in comparison to wild-type littermates, indicating hypertrophy of the 
white portion of the fibers. However, expression pattern of STK25 
assessed through immunofluorescence technique did not display any 
clear specificity for fiber types.  
Through histopathological evaluation of H&E-stained sections and 
TEM images, we identified an extensive damage in Stk25 transgenic 
muscle. Gastrocnemius muscle in Stk25 transgenic mice had 
degenerating fibers, intracellular inclusions, focal necrosis, infiltration 
of mononuclear cells and adipocyte replacement. TEM images 
revealed disorganized sarcomere structure. Further muscle damage 
was indicated by increased fibrosis, assessed through Picrosirius Red 
staining and hydroxyproline content. It has been previously shown that 
degenerating or damaged muscles may undergo a fiber-type switch 
(95). To investigate if such a compositional change of fibers occurs in 
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Stk25 transgenic muscles, we stained and counted the myosin heavy 
chain (MHC) types. However, the results suggest that there was no 
fiber type switch.   
The complex question of lipid accumulation in skeletal muscle causing 
insulin resistance has been discussed for many years (96; 97). 
Increased lipid droplet accumulation is present in individuals 
performing endurance exercise as well as in individuals with excessive 
calorie consumption. In contrast to the exercise-trained individuals, the 
obese individuals manifest metabolic dysregulation accompanied by 
inflammation, endoplasmatic reticulum stress and mitochondrial stress 
(65; 98; 99). Staining of red gastrocnemius muscle fiber types with 
Nile Red showed increased lipid accumulation in those fibers of Stk25 
transgenic mice. TEM image analysis revealed the same trend of 
increased lipid accumulation and also showed mitochondrial 
ultrastructure damage. Decrease in endurance exercise capacity in 
Stk25 transgenic mice was most likely a consequence of damaged 
skeletal muscle and disrupted mitochondrial structure and function. 
Furthermore, mitochondrial respiration, assessed through Mitotracker 
Red staining, revealed decreased activity of the mitochondria in Stk25 
transgenic gastrocnemius muscle in all red fiber types. L6 myoblasts 
transfected to overexpress Stk25 also showed excessive lipid 
accumulation and reduced mitochondrial respiration. Moving the 
perspective to a more defined system of the cell culture, the 
transfection experiments have shown a direct effect of STK25 on 
increased lipid accumulation and mitochondrial respiration.  
In concordance with reduced mitochondrial respiratory capacity in 
Stk25 transgenic gastrocnemius muscle and Stk25-overexpreesing L6 
myoblasts, enzymatic staining for oxidative phosphorylation markers 
showed that Stk25 transgenic gastrocnemius has reduced staining, 
and also likely activity, of NADH, succinate dehydrogenase and 
cytochrome c oxidase, which are three of the four complexes in the 
mitochondrial electron transport chain. This further confirms 
disturbance of mitochondrial function in skeletal muscle of Stk25 
transgenic mice. In agreement with reduced mitochondrial respiratory 
STK25 AS A REGULATOR OF LIPID ACCUMULATION  
34 
capacity, β-oxidation was decreased in skeletal muscle of Stk25 
transgenic mice. Stk25-transfected L6 myoblasts showed the same 
trend in reduction of β-oxidation. Lipid overload and impaired 
mitochondria may lead to accumulation of fatty acid oxidation 
intermediates, such as acylcarnitines, due to incomplete β-oxidation, 
subsequently affecting insulin signaling (65; 100). However, despite 
reduced β-oxidation, Stk25 transgenic muscle acylcarnitine levels 
were not changed.  
Our previous studies have demonstrated impairment in whole-body 
insulin sensitivity in Stk25 transgenic mice fed HFD (82). Organ-
specific EHC revealed a decrease in in vivo insulin-stimulated glucose 
uptake in two major skeletal muscles of Stk25 transgenic mice, 
quadriceps and gastrocnemius, and a similar tendency in soleus and 
EDL. Together, these results confirm the adverse consequences of 
lipid accumulation and mitochondrial damage coupled to STK25 
overexpression (Fig. 3). 
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Figure 3. Schematic illustration of the metabolic responses 
of Stk25 transgenic mice vs. wild-type littermates. Figure 
adapted from Paper II. 
In summary, this study, as well as previous studies on the role of 
STK25 in metabolism, has confirmed its importance in tissue lipid 
storage, mitochondrial function and insulin sensitivity during times of 
energy excess. Together, these data make STK25 antagonists an 
appealing potential target in the treatment of metabolic diseases, such 
as obesity-associated T2DM.  
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4.3 PAPER III: STK25 REGULATES LIPID 
ACCUMULATION AND MATURATION OF 
3T3-L1 CELLS 
 
Adipose tissue plays a key role in obesity and its metabolic disorders, 
such as T2DM and NAFLD/NASH (10; 28). Previous studies have 
shown a close connection between STK25 and ectopic lipid storage in 
peripheral tissues (79-84; 87; 101). The adipose tissue is the major 
organ to safely store lipids and, thus, it is essential to evaluate the 
effect of STK25 in adipocytes. For this, we have used murine 3T3-L1 
pre-adipocytes and silenced STK25 prior to their differentiation. 
Differentiated 3T3-L1 cells, where STK25 was silenced, displayed a 
major reduction in lipid accumulation without any apparent shift in lipid 
droplet size. We have repeatedly observed decreased lipid 
accumulation with STK25 silencing and knockout, in several cell lines 
and tissues (79; 81; 87).  
Decreased lipid accumulation can depend on several factors such as 
retardation of the differentiation process and/or more specific effects 
on lipid accumulation/release. To investigate if reduction in lipid 
accumulation was dependent on impaired differentiation, we examined 
expression of key transcription factors responsible for the adipocyte 
differentiation. During early differentiation, Stk25 knockdown cells had 
small or no decrease in Pparγ, C/ebpα and Srebp expression, 
suggesting that the reduced lipid accumulation was unlikely to be fully 
attributable to defective differentiation process and early induction of 
Pparγ. However, activation of Pparγ is regulated by activating ligands, 
which apparently can be formed/secreted by 3T3-L1 cells in contrast 
to the situation in human cells, which are dependent on an exogenous 
ligand for differentiation (18). 
Additional support for a positive effect of STK25 in the lipid 
accumulation process was provided by the data in human adipose 
tissue, where STK25 was positively and significantly correlated with a 
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large number of adipogenic markers. However, it should be 
emphasized that we used intact human adipose tissue biopsies rather 
than isolated adipose cells. Potential effects of other cells in the 
biopsies could contribute but it is unlikely that this would alter the 
conclusion of this more general effect of STK25 on lipid accumulation 
in different cells. 
To examine if the decreased lipid content in Stk25 knockdown 3T3-L1 
cells was associated with an increased lipolysis, we stimulated the β-
adrenergic receptors with isoproterenol. As evident by glycerol release 
and HSL phosphorylation status, lipolysis was reduced in Stk25 
knockdown.  
Decrease in ACC has been linked to increased FA oxidation in several 
studies (102; 103), and it was also observed in livers of Stk25 
knockout mice and Stk25 antisense oligonucleotide treated mice (79; 
87). Consistently, the same observation was made in Stk25 
knockdown 3T3-L1 cells both at mRNA and protein levels at total and 
specific phosphorylation site of ACC. However, it is unlikely that this 
can explain the reduced cell lipid accumulation, as mitochondrial 
activity was not altered when STK25 was silenced in differentiated 
3T3-L1 cells. As ACC is connected to FA oxidation and synthesis, 
further investigations such as evaluation of β-oxidation are needed. 
LCFAs are proposed to be endogenous ligands for PPARs (104). This 
made us hypothesize that silencing of STK25 changes 
accessibility/release of endogenous ligands that activate PPARγ. 
Indeed, several of genes (Gpr120, Glut4, Fabp4, Pgc1 and Fasn) and 
proteins (GLUT4, FABP4, PGC1, and FAS) regulated by Pparγ and its 
ligands were down-regulated by Stk25 knockdown.  
Adding to decreased lipolysis in Stk25 knockdown cells, protein 
expression of ATGL, which is the key lipolytic protein regulated by 
PPARγ (105), was also decreased. It has been shown that ATGL-
induced lipolysis is crucial for the generation of endogenous PPARα 
ligands in heart and liver (106; 107). Importantly, treatment of Stk25 
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knockdown cells with a synthetic PPAR ligand resulted in 
normalization of ATGL protein levels, improved stimulated lipolysis 
and a partial rescue in lipid accumulation. Also, expression of several 
genes and proteins regulating lipid and glucose homeostasis were 
increased following PPAR ligand treatment of Stk25 knockdown cells 
both at the early and late differentiation stage.  
Taken together, this study further supports an important role of STK25 
in lipid accumulation and metabolism. Our data also suggest that 
STK25 may contribute to the availability of lipid-derived endogenous 
ligands necessary for PPAR activation and adipose cell maturation 
(Fig. 4). 
Figure 4. Proposed mechanism of STK25 in 3T3-L1 cells. 
Low levels of STK25 reduces maturation of 3T3-L1 
preadipocytes possibly through its regulation of lipid 
accumulation and lipolysis, attenuating secretion of 
endogenous PPAR ligands.  
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5 CONCLUSIONS 
Taken together, the work in this thesis shows that STK25 plays an 
important role for lipid accumulation in three major tissues/cells; liver, 
skeletal muscles and adipose cells. Importantly, STK25 mRNA is also 
positively associated with markers of NASH progression in human 
liver biopsies making it an interesting potential future target of therapy 
in this important human disease. 
In Paper I, when mice where challenged with MCD diet to develop 
NASH, Stk25 knockout mice were protected while Stk25 transgenic 
mice progressed and developed severe steatosis, hepatocellular 
damage, inflammation and fibrosis. Also, STK25 mRNA expression in 
human liver biopsies from overweight and obese subjects was 
positively correlated with NASH features.  
Paper II also shows harmful effects of STK25 overexpression in 
skeletal muscle of mice chronically challenged with HFD. Stk25 
transgenic mice developed increased ectopic lipid accumulation, 
suppressed mitochondrial respiratory capacity and insulin resistance 
in major skeletal muscles.  
Previous metabolic studies on STK25, as well as data in Paper I, 
show that deleting STK25 is beneficial in skeletal muscle and liver by 
reducing lipid overload, as well as improving systemic insulin 
sensitivity, in obese mice with ectopic lipid accumulation. Adipose 
tissue, on the other hand, is the primary and best site for lipid storage. 
In Paper III, using the murine preadipocyte 3T3-L1 cells, we found 
adipose cell maturation and lipid accumulation to be reduced during 
adipogenesis by silencing STK25. Although the mechanisms for this 
were not fully resolved, an interesting finding was that the addition of a 
synthetic PPARγ ligand essentially prevented the reduction in 
adipogenic maturation in this model. Thus, down-regulation of STK25 
in adipose cells may lead to decreased production/release of 
endogenous lipid-derived ligands that serve as activators of Pparγ and 
adipocyte differentiation, resulting in decreased lipid accumulation and 
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maturation of these cells. The association between STK25 expression 
and adipose cell maturation and lipid accumulation is also supported 
by the positive correlations between STK25 and several differentiation 
markers in human adipose tissue. However, no changes in adipocyte 
differentiation have been observed in STK25 knockout and transgenic 
mouse models (85). Thus, further studies are necessary to understand 
the role of STK25 in adipocyte function. 
Based on the work in this thesis as well as previous studies on STK25 
in relation to metabolic diseases, we conclude that STK25 is tightly 
integrated with lipid accumulation and ectopic lipid deposition in 
peripheral tissues in obesity. Its association with markers of 
NAFLD/NASH progression, in particular, makes it an attractive target 
for drug development in this disease.  
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